Arunava Das*, Avik Mandal, Ujjwal Manna and Manas Chakraborty

Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and A.H.S, WB, India

*Corresponding Author: Arunava Das, Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and A.H.S, WB, India.

Received: February 14, 2022; Published: March 19, 2021

Abstract

SARS-CoV-2 is the viral pathogen that is abbreviated as “Severe Acute Respiratory Syndrome Coronavirus 2” and responsible for the disease known as Corona Virus Disease 2019 or COVID-19. What started as a few individual cases linking to a Fish Market situated in Wuhan, China, quickly took the form of a global pandemic in the span of upcoming 6 months with around 4 million cases of COVID-19 along with 7million death worldwide as of in June 2021. Through various studies done by multiple medical institutes a relation between COVID-19 progression and resulting cytokine storm has been established. This further enables us to develop treatments that decreases the disease severity.

References

1. Paules CI., et al. “Coronavirus infections— more than just the common cold”. JAMA8 (2020): 707-708.
2. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
3. Crayne CB., et al. “The immunology of macrophage activation syndrome”. Frontiers in Immunology 10 (2019): 119.
4. Ding Y., et al. “Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS- CoV) in SARS patients: implications for pathogenesis and virus transmission pathways”. Journal of Pathology 203 (2004): 622-630.
5. Sarzi-Puttini P., et al. “COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?”. Clinical and Experimental Rheumatology 2 (2020): 337-342.
6. Li X., et al. “Molecular immune pathogenesis and diagnosis of COVID-19”. Journal of Pharmaceutical Analysis (2020).
7. Read R. “Flawed methods in “COVID-19: attacks the 1-betachain of hemoglobin and captures the porphyrin to inhibit humanheme metabolism”. ChemRxiv Preprint (2020).
8. Wenzhong L and Hualan L. “COVID-19:attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism”. ChemRxiv Preprint (2020).
9. Zhang W., et al. “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China”. Clinical Immunology (2020): 108393.
10. Schnappauf O., et al. “The Pyrin inflammasome in health and disease”. Frontiers in Immunology 10 (2019): 1745.
11. Lucherini OM., et al. “Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases”. Clinical and Experimental Rheumatology 36 (2018): 3-9.
12. Barrat FJ., et al. “Importance of nucleic acid recognition in inflammation and autoimmunity”. Annual Review of Medicine 67 (2016): 323-336.
13. Zalinger ZB., et al. “MDA5 is critical to host defense during infection with murine coronavirus”. Journal of Virology 24 (2015): 12330-12340.
14. Crow MK., et al. “Type I interferons in host defense and inflammatory diseases”. Lupus Science Medicine1 (2019): e000336.
15. Al-Samkari H and Berliner N. “Hemophagocytic lymph histiocytosis”. Annual Review of Pathology: Mechanisms of Disease 13 (2018): 27-49.
16. Mehta P., et al. “COVID- 19: consider cytokine storm syndromes and immunosuppression”. Lancet 10229 (2020): 1033-1034.
17. Lamborn IT., et al. “Recurrent rhinovirus infections in a child with inherited MDA5 deficiency”. Journal of Experimental Medicine 7 (2017): 1949-1972.
18. Stebbing J., et al. “COVID-19: combining antiviral and anti-inflammatory treatments”. Lancet Infectious Disease 4 (2020): 400-402.
19. Ferro F., et al. “COVID-19: the new challenge for rheumatologists”. Clinical and Experimental Rheumatology 2 (2020): 175-180.
20. Gao J., et al. “Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends1 (2020): 72-73.
21. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 1 (2005): 69.
22. Jamilloux Y., et al. “JAK inhibitors for the treatment of auto-immune and inflammatory diseases”. Autoimmune Review (2019): 102390.
23. Richardson P., et al. “Baricitinib as potential treatment for 2019-nCoV acute respiratory disease”. Lancet10223 (2020): 30.
24. Favalli EG., et al. “Baricitinib for COVID-19: a suitable treatment?” Lancet Infectious Disease (2020).
25. Dholaria BR., et al. “Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities”. BioDrugs 1 (2019): 45-60.
26. Ding C and Jones G. “Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases”. Reviews on Recent Clinical Trials 13 (2006): 193-200.
27. Şahin A., et al. “Assessment of effectiveness of anakinra and canakinumab in patients with colchicine- resistant/unresponsive familial Mediterranean fever”. Advances in Rheumatology1 (2020): 12.
28. Shakoory B., et al. “Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior phase III trial”. Critical Care Medicine2 (2016): 275-281.

Citation

Citation: Arunava Das., et al. “Cytokine Storm in COVID-19”. Acta Scientific Computer Sciences 3.1 (2022): 03-08.

Copyright

Copyright: © 2022 Arunava Das., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.